Interactions of the public and private sectors in drug development: Boundaries to protect scientific values while preserving innovation

Gail H. Cassell, PhD, DSc (hon)
Vice President, Scientific Affairs, and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company, Indianapolis, IN

Correspondence: Gail H. Cassell, PhD, DSc (hon), Vice President, Scientific Affairs, and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285; [email protected]

Acknowledgment: The author gratefully acknowledges helpful discussions with H. Heath, A. Norris, L.E. Van Campen, M.C. Jones, G. Geipel, and S.M. Paul of Eli Lilly and Company; E. Holmes of the University of California, San Diego; and M.G. Edwards of Recombinant Capital.

Dr. Cassell reported that she has no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article apart from her employment with Eli Lilly and Company, through which she receives a salary, grant/research support, and stock options.

Gail H. Cassell, PhD, DSc (hon)
Vice President, Scientific Affairs, and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company, Indianapolis, IN

Correspondence: Gail H. Cassell, PhD, DSc (hon), Vice President, Scientific Affairs, and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285; [email protected]

Acknowledgment: The author gratefully acknowledges helpful discussions with H. Heath, A. Norris, L.E. Van Campen, M.C. Jones, G. Geipel, and S.M. Paul of Eli Lilly and Company; E. Holmes of the University of California, San Diego; and M.G. Edwards of Recombinant Capital.

Dr. Cassell reported that she has no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article apart from her employment with Eli Lilly and Company, through which she receives a salary, grant/research support, and stock options.

Gail H. Cassell, PhD, DSc (hon)
Vice President, Scientific Affairs, and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company, Indianapolis, IN

Correspondence: Gail H. Cassell, PhD, DSc (hon), Vice President, Scientific Affairs, and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285; [email protected]

Acknowledgment: The author gratefully acknowledges helpful discussions with H. Heath, A. Norris, L.E. Van Campen, M.C. Jones, G. Geipel, and S.M. Paul of Eli Lilly and Company; E. Holmes of the University of California, San Diego; and M.G. Edwards of Recombinant Capital.

Dr. Cassell reported that she has no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article apart from her employment with Eli Lilly and Company, through which she receives a salary, grant/research support, and stock options.